Results 51 to 60 of about 5,561 (207)

Novel Psychoactive Substances: : the pharmacology of stimulants and hallucinogens [PDF]

, 2016
This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Review of Clinical Pharmacology, on March 2016, available online at doi: : http://www.tandfonline.com/doi/full/10.1586/17512433.2016.1167597.There are increasing levels ...
Corkery JM, Daly M, Dargan PI, Fabrizio Schifano, Farrè M, G. Duccio Papanti, John M. Corkery, Laura Orsolini, Shulgin AT, Shulgin AT, Soussan C, Ujváry I   +11 more
core   +3 more sources

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

Hallucinogen Rating Scale (HRS) - A Brazilian version: translation and cross-cultural adaptation [PDF]

, 2011
BACKGROUND: There is a growing scientific interest in the effects of hallucinogens in general and the religious use of psychoactive brew ayahuasca in Brazil in particular.
Barbosa, Paulo César Ribeiro, Mizumoto, Suely, Silveira, Dartiu Xavier da, Strassman, Rick J.   +3 more
core   +3 more sources

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

Adolescent brain cognitive development (ABCD) study: Overview of substance use assessment methods. [PDF]

, 2018
One of the objectives of the Adolescent Brain Cognitive Development (ABCD) Study (https://abcdstudy.org/) is to establish a national longitudinal cohort of 9 and 10 year olds that will be followed for 10 years in order to prospectively study the risk and
Bartsch, Hauke, Conway, Kevin P, Feldstein Ewing, Sarah W, Goldstein, Rita Z, Gonzalez, Raul, Heitzeg, Mary, Lisdahl, Krista M, Nixon, Sara Jo, Sher, Kenneth J, Tapert, Susan   +9 more
core   +2 more sources

Changes over time in hallucinogen‐related emergency department visits in Ontario, Canada

Addiction, EarlyView.
Abstract Background and aims Recent increasing interest in hallucinogens has underscored the critical gaps in our understanding of their adverse health effects and healthcare usage over time. The current study aimed to examine changes in emergency department (ED) visit rates involving hallucinogens, clinical outcomes of visits and the characteristics ...
Daniel T. Myran, Rachael MacDonald‐Spracklin, Alexander R. Levesque, Michael Pugliese, Jess G. Fiedorowicz, André J. McDonald, Joshua D. Rosenblat, Ian Colman, Josephine Zein, Marco Solmi   +9 more
wiley   +1 more source

Ayahuasca: A review of historical, pharmacological, and therapeutic aspects

PCN Reports, 2023
Ayahuasca is a psychedelic plant brew originating from the Amazon rainforest. It is formed from two basic components, the Banisteriopsis caapi vine and a plant containing the potent psychedelic dimethyltryptamine (DMT), usually Psychotria viridis.
Simon G. D. Ruffell, Max Crosland‐Wood, Rob Palmer, Nige Netzband, WaiFung Tsang, Brandon Weiss, Sam Gandy, Tessa Cowley‐Court, Andreas Halman, Diana McHerron, Angelina Jong, Tom Kennedy, Eleanor White, Daniel Perkins, Devin B. Terhune, Jerome Sarris   +15 more
doaj   +1 more source

Safety pharmacology of acute mescaline administration in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aims Psychedelics, including mescaline, may serve as novel treatments for depression and anxiety. However, data is scarce on the safety of mescaline. Methods The present pooled analysis included two double‐blind, randomized, placebo‐controlled studies with a total of 48 participants and 96 mescaline administrations. Single oral‐dose administrations (n =
Aaron Klaiber, Mélusine Humbert‐Droz, Laura Ley, Yasmin Schmid, Matthias E. Liechti   +4 more
wiley   +1 more source

Effects of hallucinogenic drugs on the human heart

Frontiers in Pharmacology
Hallucinogenic drugs are used because they have effects on the central nervous system. Their hallucinogenic effects probably occur via stimulation of serotonin receptors, namely, 5-HT2A-serotonin receptors in the brain.
Joachim Neumann, Stefan Dhein, Uwe Kirchhefer, Britt Hofmann, Ulrich Gergs   +4 more
doaj   +1 more source

N, N-Dimethyltryptamine and Biological Reductive Accounts for Religious and Spiritual Experiences [PDF]

, 2014
There is unquestionably a plethora of details and mysteries regarding the mind and the body. However, with the advent of psychopharmacology (the study of how psychedelics inform or alter brain states), there are more issues at hand. Do psychedelics allow
Smith, Shaun
core   +1 more source